These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36727047)

  • 1. Impact of clinicopathological factors on extended endocrine therapy decision making in estrogen receptor-positive breast cancer.
    Chen W; Wu J; Zhu Y; Huang J; Chen X; Huang O; He J; Li Y; Chen W; Shen K; Zhu L
    Front Oncol; 2022; 12():996522. PubMed ID: 36727047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical usefulness of the CTS5 in the prediction of late distant recurrence in postmenopausal women with estrogen receptor-positive early breast cancer.
    Tajiri W; Ijichi H; Takizawa K; Koi Y; Masuda T; Ueo H; Koga C; Nakamura Y; Taguchi K; Okamoto M; Tokunaga E
    Breast Cancer; 2021 Jan; 28(1):67-74. PubMed ID: 32601800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of CTS5 on a Retrospective Cohort of Real-Life Pre- and Postmenopausal Patients Diagnosed With Estrogen Receptor-Positive Breast Cancers: Is It Prognostic?
    Villasco A; Agnelli F; D'Alonzo M; Accomasso F; Sismondi P; Biglia N
    Clin Breast Cancer; 2021 Feb; 21(1):e53-e62. PubMed ID: 32703705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?
    Wimmer K; Hlauschek D; Balic M; Pfeiler G; Greil R; Singer CF; Halper S; Steger G; Suppan C; Gampenrieder SP; Helfgott R; Egle D; Filipits M; Jakesz R; Sölkner L; Fesl C; Gnant M; Fitzal F
    Breast Cancer Res Treat; 2024 Jun; 205(2):227-239. PubMed ID: 38273214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Utility of Breast Cancer Index (BCI) Over Clinical Prognostic Tools for Predicting the Need for Extended Endocrine Therapy: A Safety Net Hospital Experience.
    Shah S; Shaing C; Khatib J; Lodrigues W; Dreadin-Pulliam J; Anderson BB; Unni N; Farr D; Li HC; Sadeghi N; Syed S
    Clin Breast Cancer; 2022 Dec; 22(8):823-827. PubMed ID: 36089460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Treatment Score Post-5 Years as a Tool for Risk Estimation of Late Recurrence in Thai Patients With Estrogen-Receptor-Positive, Early Breast Cancer: A Validation Study.
    Dejthevaporn T; Patanayindee P
    Breast Cancer (Auckl); 2023; 17():11782234231186869. PubMed ID: 37533837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer.
    Richman J; Ring A; Dowsett M; Sestak I
    Breast Cancer Res Treat; 2021 Feb; 186(1):115-123. PubMed ID: 33222093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of late recurrence prediction by gene expression profiles and clinicopathological factors in estrogen receptor-positive breast cancer.
    Kitano S; Tsunashima R; Kato C; Watanabe A; Sota Y; Matsumoto S; Morita M; Sakaguchi K; Naoi Y
    Breast Cancer; 2024 Sep; 31(5):898-908. PubMed ID: 38862868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the Breast Cancer Index for Extended Endocrine Decision-Making: First Results of the Prospective BCI Registry Study.
    Sanft TB; Wong J; O'Neal B; Siuliukina N; Jankowitz RC; Pegram MD; Fox JR; Zhang Y; Treuner K; O'Shaughnessy JA
    J Natl Compr Canc Netw; 2024 Mar; 22(2):99-107. PubMed ID: 38437792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials.
    Noordhoek I; Blok EJ; Meershoek-Klein Kranenbarg E; Putter H; Duijm-de Carpentier M; Rutgers EJT; Seynaeve C; Bartlett JMS; Vannetzel JM; Rea DW; Hasenburg A; Paridaens R; Markopoulos CJ; Hozumi Y; Portielje JEA; Kroep JR; van de Velde CJH; Liefers GJ
    J Clin Oncol; 2020 Oct; 38(28):3273-3281. PubMed ID: 32706636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivors.
    Sella T; Zheng Y; Rosenberg SM; Ruddy KJ; Gelber SI; Tamimi RM; Peppercorn JM; Schapira L; Borges VF; Come SE; Carey LA; Winer EP; Partridge AH
    NPJ Breast Cancer; 2023 Apr; 9(1):31. PubMed ID: 37185922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of Clinical Treatment Score post-5 years (CTS5) risk stratification in premenopausal breast cancer patients and Ki-67 labelling index.
    Lee J; Cha C; Ahn SG; Kim D; Park S; Bae SJ; Kim J; Park HS; Park S; Kim SI; Park BW; Jeong J
    Sci Rep; 2020 Oct; 10(1):16850. PubMed ID: 33033359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of the Clinical Treatment Score Post-Five Years in Breast Cancer Patients for Predicting Late Distant Recurrence: A Single-Center Investigation in Korea.
    Lee JH; Lee SK; Chae BJ; Yu J; Lee JE; Kim SW; Nam SJ; Ryu JM
    Front Oncol; 2021; 11():691277. PubMed ID: 34239805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxicity of extended adjuvant endocrine with aromatase inhibitors in patients with postmenopausal breast cancer: A Systemtic review and Meta-analysis.
    Zhao F; Ren D; Shen G; Ahmad R; Dong L; Du F; Zhao J
    Crit Rev Oncol Hematol; 2020 Dec; 156():103114. PubMed ID: 33045493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR
    Noordhoek I; Treuner K; Putter H; Zhang Y; Wong J; Meershoek-Klein Kranenbarg E; Duijm-de Carpentier M; van de Velde CJH; Schnabel CA; Liefers GJ
    Clin Cancer Res; 2021 Jan; 27(1):311-319. PubMed ID: 33109739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Treatment Score post-5 years as a predictor of late distant recurrence in hormone receptor-positive breast cancer: systematic review and meta-analysis.
    Shrestha A; Cullinane C; Evoy D; Geraghty J; Rothwell J; Walshe J; McCartan D; McDermott E; Prichard R
    Br J Surg; 2022 Apr; 109(5):411-417. PubMed ID: 35194632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer.
    Sanft T; Aktas B; Schroeder B; Bossuyt V; DiGiovanna M; Abu-Khalaf M; Chung G; Silber A; Hofstatter E; Mougalian S; Epstein L; Hatzis C; Schnabel C; Pusztai L
    Breast Cancer Res Treat; 2015 Dec; 154(3):533-41. PubMed ID: 26578401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct comparison of three different mathematical models in two independent datasets of EUSOMA certified centers to predict recurrence and survival in estrogen receptor-positive breast cancer: impact on clinical practice.
    Iacuzzo C; Giudici F; Scomersi S; Ceccherini R; Zanconati F; Generali D; Bortul M
    Breast Cancer Res Treat; 2021 Jun; 187(2):455-465. PubMed ID: 33646494
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.